The big reward to shareholders will be via the increase in share price once the Phase 3 trials are successful.
The first step is to start, and complete, the Phase 3 trial. This is the primary focus of the company at the present time, and includes securing the funding to run the trial.
If the Management are confident in Trofinetide (and it appears they are) then the best deal would be one with a smaller upfront payment (sufficient to fund the Phase 3 trials) and a larger back-end arrangement that retains a lager portion of future revenue for the company and it's shareholders.
What will the deal be like? Head vs heart, page-58
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.96 |
Change
-2.150(9.30%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $22.50 | $22.70 | $20.28 | $24.29M | 1.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 259 | $20.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.98 | 1641 | 2 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.07 |
Change
-2.150 ( 9.39 %) |
||||
| Open | High | Low | Volume | ||
| $22.45 | $22.67 | $20.27 | 399615 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| NEU (ASX) Chart |